A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
Study sponsor: Relay Therapeutics, Inc. · RLAY
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2029-05-31Estimated
Enrollment · participants180Estimated
Source updated2026-11-03Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.